Full Press Release Details
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress on June 25, 2022.
ALT
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress on June 25, 2022
Key Takeaway: Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress on June 25, 2022
Price reaction · baseline $7.34 (2022-06-16 close) · hit after-hours · clean, no other ALT news in the window
day 0 close
+22.9%
day 1
+27%
day 3 · peak
+44.4%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight